Application of Allogeneic Bone Marrow Cells in View of Residual Alloreactivity: Sirolimus but Not Cyclosporine Evolves Tolerogenic Properties
Table 2
Survival of heart grafts transplanted to irradiated BMT recipients at day 16 after BMT (during T cell recovery of recipients).